Goldman Sachs has initiated coverage on Sotera Health with a buy rating, pointing to the company's durable business model and strong competitive position in the medical sterilisation and laboratory testing sectors. The investment bank's analysts believe the firm's long-term contracts and essential service nature provide a stable revenue base, even as the broader healthcare sector faces pricing pressures.
Sotera Health, headquartered in the United States, operates through its Steris and Nordion brands, offering sterilisation services critical to the medical device and pharmaceutical industries. The company has faced legal challenges related to its use of ethylene oxide, a sterilising agent linked to cancer risks in some communities. However, Goldman Sachs views the litigation risk as manageable, with the core business underpinned by high barriers to entry and recurring demand.
The initiation comes at a time when the FTSE 100 and FTSE 250 indices have experienced volatility, with the FTSE 100 closing at 7,642.34 points on Tuesday, down 0.3 per cent, as investors weighed interest rate uncertainty and geopolitical tensions. For UK investors and pension holders with exposure to global healthcare stocks, Sotera Health's defensive profile could offer a hedge against market swings. The sterilisation sector is seen as non-discretionary, meaning demand remains steady regardless of economic cycles.
Analysts at Goldman Sachs noted that Sotera Health's revenue is backed by multi-year contracts with major pharmaceutical and medical device companies, providing visibility into future cash flows. The company also benefits from regulatory tailwinds, as stricter sterilisation standards in the EU and UK drive demand for specialised services. 'The durable nature of the model, combined with a strong market position, supports a premium valuation,' the analysts wrote in a note to clients.
For UK pension funds and institutional investors, Sotera Health's inclusion in the buy-rated universe could prompt portfolio adjustments, particularly among those seeking exposure to healthcare infrastructure. The company's shares trade on the New York Stock Exchange, meaning UK investors may need to consider currency risk and American Depositary Receipt structures when evaluating the stock.
Source: Goldman Sachs research note on Sotera Health.